In April 2011, sanofi-aventis paid $20.1 billion to acquire Genzyme, a company that was only founded 30 years previously. At the LES Spring Life Sciences meeting in Boston, Dr. David Meeker, President and Chief Executive Officer of Genzyme and key note speaker, examined the history of lessons learned and critical success factors, including licensing, that created such tremendous value for Genzyme’s shareholders, and more importantly, for the patients’ lives transformed by Genzyme’s therapies.

Seminar Information
Seminar Date:
June 19, 2012
Licensing as a Source of Innovation
Individual topic purchase: Selected
Online Materials
LES Member Price:$0.00
Non-Member Price:$0.00